Dietary advice is often proposed for patients with GERD. Previous studies demonstrated that a low-FODMAPs diet improved lower gastrointestinal symptoms. Colonic fermentation of alimentary carbohydrates has been shown to impact gastric and oesophageal motility and the occurrence of reflux episodes.
The current multicentre, randomised, open-label study from France compared the efficacy of a 4-week low-FODMAPs diet with a standard diet in 31 patients (55% female, median age 45 years) with symptomatic PPI-refractory GERD, defined by a Reflux Disease Questionnaire (RDQ) score >3 and abnormal pH-impedance monitoring on PPIs [1].
Adherence to the assigned diet was good. There was a significant difference in the amount of FODMAPS consumed per day between the low-FODMAPs diet and the standard diet group (2.5 g vs 13 g, respectively; P<0.001). Furthermore, the caloric intake decreased in both groups (from 1,600 to 1,400 kcal on average, P<0.001) without significant differences between the 2 groups. There was also no significant difference in response rates (RDQ score ≤3) between the low-FODMAPs diet and standard-diet groups (37.5% vs 20%; P=0.20).
The primary endpoint was the percentage of responder patients (RDQ ≤3) at the end of the 4 weeks. Total RDQ score and dyspepsia subscore decreased significantly over time in both groups (P=0.002) These was no difference according to the assigned diet group (P=0.85).
The secondary endpoints evaluated the effect of the diet on pH-impedance parameters and associated functional symptoms (dyspepsia, irritable bowel syndrome [IBS]), using different scores, including the Gastrointestinal Quality of Life Index (GIQLI) and the IBS-Severity Scoring System (IBS-SSS).
The IBS-SSS decreased in both groups, but this was only significant for the FODMAPS group (P=0.04). There was no difference in the GIQLI score. Moreover, there was no significant difference in the pH-impedance parameters between the low-FODMAPs diet and standard diet.
This study demonstrated that a low-FODMAPs diet did not show any benefit over a standard diet to improve symptoms in patients with PPI-refractory GERD.
- Zerbib F. Low-FODMAPS diet for the treatment of refractory gastroesophageal reflux disease. A randomized controlled trial. UEG Week Virtual Symposium 2020, abstract OP194.
Posted on
Previous Article
« Probiotic provides a potential adjuvant treatment to gluten-free diet Next Article
Sustained efficacy of mirikizumab in moderate-to-severe Crohn’s disease »
« Probiotic provides a potential adjuvant treatment to gluten-free diet Next Article
Sustained efficacy of mirikizumab in moderate-to-severe Crohn’s disease »
Table of Contents: UEGW 2020
Featured articles
Risk factors for severe COVID-19 among IBD patients
UEGW Round-Up Articles
Sustained efficacy of mirikizumab in moderate-to-severe Crohn’s disease
Low-FODMAPs diet does not improve PPI-refractory GERD
Probiotic provides a potential adjuvant treatment to gluten-free diet
Cholecystectomy does not affect mortality in elderly patients
No improvements of remission with etrolizumab in ulcerative colitis
Filgotinib effective as maintenance treatment for ulcerative colitis
Possible causal link between eosinophilic inflammation and anxiety
Dupilumab improves in diverse aspects of eosinophilic oesophagitis
Plecanatide effective for IBS with constipation
Sustained response to faecal microbiota transplantation
Endoscopy can be delivered safely during the COVID-19 pandemic
Adenoma detection rate improves over time
Post-colonoscopy colorectal cancers in IBD patients
Risk factors for severe COVID-19 among IBD patients
First randomised T2T trial using endoscopy to guide dose escalation
Related Articles
October 28, 2020
In utero exposure to IBD drugs doesn’t up kids’ infection risk
March 12, 2021
Olamkicept may induce response in IBD patients
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com